<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01000025</url>
  </required_header>
  <id_info>
    <org_study_id>BR26</org_study_id>
    <secondary_id>CAN-NCIC-BR26</secondary_id>
    <secondary_id>PFIZER-CAN-NCIC-BR26</secondary_id>
    <secondary_id>CDR0000657246</secondary_id>
    <nct_id>NCT01000025</nct_id>
  </id_info>
  <brief_title>PF-00299804 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Standard Therapy for Advanced or Metastatic Cancer</brief_title>
  <official_title>A Double Blind Placebo Controlled Randomized Trial of PF-804 in Patients With Incurable Stage IIIB/IV Non-Small Cell Lung Cancer After Failure of Standard Therapy for Advanced or Metastatic Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: PF-00299804 may stop the growth of tumor cells by blocking some of the enzymes
      needed for cell growth. It is not yet known whether PF-00299804 is more effective than a
      placebo in treating patients with advanced non-small cell lung cancer.

      PURPOSE: This randomized phase III trial is studying PF-00299804 to see how well it works
      compared with a placebo in treating patients with stage IIIB or stage IV non-small cell lung
      cancer that has not responded to standard therapy for advanced or metastatic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To compare overall survival in patients with incurable stage III or IV non-small cell
           lung cancer receiving PF-00299804 versus placebo after failure of standard therapy for
           advanced metastatic disease.

      Secondary

        -  To compare overall survival in KRAS-WT patients between the two arms.

        -  To compare overall survival in EGFR-mutant patients between the two arms.

        -  To compare progression-free survival between arms.

        -  To compare objective response rates between arms.

        -  To estimate time to response and response duration in these patients.

        -  To evaluate the nature, severity, and frequency of toxicities between arms.

        -  To compare quality of life between arms.

        -  To determine the incremental cost-effectiveness and cost-utility ratios for PF-00299804.

        -  To correlate the expression of tumor and blood markers (at diagnosis) with outcomes and
           response.

      OUTLINE: This is a multicenter study. Patients are stratified according to center,
      performance status (0 or 1 vs 2 or 3), tobacco use (never vs past or present), best response
      to prior EGFR tyrosine kinase inhibitor (progressive disease vs other), weight loss (&lt; 5% vs
      ≥ 5% or unknown), and ethnicity (East Asian vs other). Patients are randomized to 1 of 2
      treatment arms.

        -  Arm I: Patients receive oral PF-00299804 once daily. Treatment repeats every 28 days in
           the absence of disease progression or unacceptable toxicity.

        -  Arm II: Patients receive oral placebo once daily. Treatment repeats every 28 days in the
           absence of disease progression or unacceptable toxicity.

      Blood, serum, plasma, and tissue samples are collected and examined for biomarkers and gene
      mutations, and may be banked for future studies.

      Patients complete quality-of-life questionnaires EORTC QLQ-C30 and other questionnaires at
      baseline and then periodically during and after completion of study treatment.

      Cost effectiveness and cost utility of PF-00299804 is assessed via the Health Utilities Index
      (EQ-5D) and the Resource Utilization Assessment periodically.

      After completion of study treatment, patients are followed at 4 weeks and then every 12 weeks
      thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>42 Months</time_frame>
    <description>Median and 95% confidence intervals</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival in KRAS-WT Patients</measure>
    <time_frame>42 Months</time_frame>
    <description>Median and 95% confidence intervals of Overall survival in KRAS-WT patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival in EGFR-mutant Patients</measure>
    <time_frame>42 Months</time_frame>
    <description>Overall survival by EGFR-mutantion subgroups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>42 Months</time_frame>
    <description>progression were evaluated using the revised international criteria (1.1) proposed by the RECIST (Response Evaluation Criteria in Solid Tumours) committee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>42 months</time_frame>
    <description>Response were evaluated in this study using the revised international criteria (1.1) proposed by the RECIST (Response Evaluation Criteria in Solid Tumours) committee. BEST RESPONSE from the start of study treatment until the end of treatment were reported.Objective response rate is the sum of CR + PR divided by the total number of patients in each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Toxicity as Measured by NCI CTCAE Version 4.0</measure>
    <time_frame>42 Months</time_frame>
    <description>Number of participants with Toxicities by treatment received according to NCI CTCAE version 4.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">720</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>PF-00299804</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive oral PF-00299804 once daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive oral placebo once daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-00299804</intervention_name>
    <description>PF-804 45 mg PO, daily</description>
    <arm_group_label>PF-00299804</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 45 mg PO, daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Eligibility Criteria

          -  Histologically confirmed diagnosis of non-small cell carcinoma of the lung. Patients
             must have an adequate histopathology or cytology specimen must consent to release of
             all specimens for this protocol, and the centre/pathologist must have agreed to
             submission of the specimens.

          -  Patients must have evidence of disease, but measurable disease is not mandatory. To be
             considered evaluable for complete or partial response assessment, patients must have
             at least one measurable lesion as follows:

        X-ray ≥ 20 mm Spiral CT scan or physical exam ≥ 10 mm (lymph nodes must be ≥ 15 mm in the
        short axis); Measurable lesions must be outside a previous radiotherapy field if they are
        the sole site of disease, unless disease progression has been documented.

          -  Male or female, 18 years of age or older.

          -  ECOG performance status of 0, 1, 2 or 3. Patients with performance status of 3 are
             eligible providing that the investigator attests that the patient has a reasonable
             life expectancy (≥ 6 weeks).

          -  Adequate renal and hepatic functions as defined by the following required laboratory
             values obtained within 14 days prior to randomization. If anemic, patients should be
             asymptomatic and should not be decompensated.

        Creatinine &lt;1.5 upper limit of normal Total bilirubin &lt; 1.5 upper limit of normal ALT
        (SGPT) &lt; 2.5 times the upper limit of normal. Note: If clearly attributable to liver
        metastasis, ALT (SGPT) values &lt; 5 times the upper limit of normal are permitted.

        - Previous Therapy Failure of a treatment regimen is defined as the inability to continue a
        regimen for any reason including, but not limited to, progressive disease, toxicity, or
        patient request. Up to a maximum of three lines of chemotherapy for advanced/metastatic
        disease (defined below) and at least one of erlotinib or gefitinib for advanced/ metastatic
        disease (defined below) should have failed.

        Exchange of one chemotherapy agent for another within a combination chemotherapy regimen is
        not considered a new regimen in the following circumstances

          -  carboplatin is substituted for cisplatin due to nephrotoxicity

          -  one agent in the combination regimen is changed due to hypersensitivity occurring in
             the first cycle.

        Chemotherapy for Advanced/Metastatic Disease:

        Patients must have recovered from any reversible toxic effects and at least 21 days must
        have elapsed from the last dose and prior to randomization (14 days from the last dose for
        chemotherapy regimens administered on a weekly schedule). Further palliative cytotoxic
        chemotherapy must not be planned.

        Patients &lt; 70 years:

        • Must have received 1 and up to a maximum of 3prior chemotherapy regimens (at least one of
        the three must have been a combination regimen and at least one must have contained
        platinum).

        Patients ≥ 70 years (generally accepted as being at the time of the administration of the
        first regimen of chemotherapy for advanced disease):

        • Must have received 1 and up to a maximum of 3 prior chemotherapy regimens for their
        disease. These may have been single agent chemotherapy regimens and a platinum agent is not
        required in keeping with current standards of practice.

        Adjuvant Chemotherapy: Patients may ALSO have had prior adjuvant therapy for completely
        resected disease, providing completed at least 12 months prior to randomization. Adjuvant
        regimens &lt; 12 months prior to randomization and combined chemotherapy/radiation regimens
        for irresectable locally advanced stage III disease (irrespective of timing), are
        considered to be for advanced/metastatic disease and constitute one of the 3 permissible
        regimens. Patients must have recovered from any reversible treatment related toxicities
        prior to randomization.

        EGFR Inhibitor Therapy: Patients may only be enrolled after failure of prior gefitinib or
        erlotinib for advanced or metastatic disease. Patients who have received adjuvant gefitinib
        or erlotinib for completely resected NSCLC and who have recurred &lt; 12 months after
        discontinuing erlotinib or gefitinib are eligible. Patients who received gefitinib or
        erlotinib for neoadjuvant therapy only are not eligible. EGFR inhibitor therapy must have
        been discontinued at least 21 days prior to randomization. Patients who discontinued prior
        gefitinib or erlotinib therapy for severe or life threatening organ toxicity are not
        eligible. Patients may also have received other EGFR active agents (such as reversible oral
        agents or monoclonal antibodies or vaccines) in addition to erlotinib or gefitinib but may
        not have received ANY prior irreversible EGFR inhibitor such as BIBW2992, HKI-272
        (neratinib).

        Maintenance Therapy: The same chemotherapy or agent/s continued for longer than 4-6 cycles
        for the purposes of 'maintenance' is considered one regimen; if another chemotherapy agent
        is given with 'maintenance' intent, it is considered a second regimen providing that
        'failure' is documented. Patients who received erlotinib or gefitinib with 'maintenance'
        intent after completion of 1st line chemotherapy are eligible providing that 'failure' is
        documented.

        Radiation: Patients may have had prior radiation therapy provided that a minimum of 14 days
        has elapsed between the end of radiotherapy and randomization onto the study. (Exceptions
        may be made however, for low dose, non-myelosuppressive radiotherapy. Patients must have
        recovered from any acute toxic effects from radiation prior to randomization.

        Previous Surgery: Previous surgery is permitted provided that wound healing has occurred
        and at least 14 days have elapsed (major surgery).

          -  Patient able (i.e. sufficiently fluent) and willing to complete the quality of life
             questionnaires. The baseline assessment must already have been completed. Inability
             (illiteracy, loss of sight, or other equivalent reason) to complete the questionnaires
             will not make the patient ineligible for the study. However, ability but unwillingness
             to complete the questionnaires will make the patient ineligible.

          -  Patient consent must be appropriately obtained in accordance with applicable local and
             regulatory requirements. Each patient must sign a consent form prior to enrollment in
             the trial to document their willingness to participate.

          -  Patients must be accessible for treatment and follow-up. All randomized patients must
             be followed and treated at participating centres. Investigators must assure themselves
             the patients randomized on this trial will be available for complete documentation of
             the treatment, adverse events, and follow-up.

          -  In accordance with NCIC CTG policy, protocol treatment is to begin within 2 working
             days of patient randomization.

        Ineligibility Criteria

        Patients who fulfill any of the following criteria are not eligible for admission to the
        study:

          -  Patients receiving concurrent treatment with other experimental drugs or anti-cancer
             therapy.

          -  Patients who have experienced untreated and/or uncontrolled cardiovascular conditions
             and/or have symptomatic cardiac dysfunction (unstable angina, congestive heart
             failure, myocardial infarction within the previous year or cardiac ventricular
             arrhythmias requiring medication, history of 2nd or 3rd degree atrioventricular
             conduction defects). Patients with a significant cardiac history, even if controlled,
             should have a LVEF &gt; 50%.

          -  Patients with untreated brain or meningeal metastases are not eligible (CT scans are
             not required to rule this out unless there is a clinical suspicion of CNS disease).
             Patients with treated CNS disease who have radiologic or clinical evidence of stable
             brain metastases, with no evidence of cavitation or hemorrhage in the brain lesion,
             are eligible providing that they are asymptomatic and do not require corticosteroids
             (must have discontinued steroids at least 1 week prior to randomization).

          -  Patients with active or uncontrolled infections, or with serious illnesses or medical
             conditions which would not permit the patient to be managed according to the protocol,
             including

               -  Severe dry eye syndrome

               -  Keratoconjunctivitis sicca

               -  Sjogren's syndrome

               -  Severe exposure keratopathy

               -  Disorders that might increase the risk for epithelium-related complications
                  (e.g., bullous keratopathy, aniridia, severe chemical burns, neutrophilic
                  keratitis)

               -  Uncontrolled inflammatory gastrointestinal diseases (Crohn's, ulcerative colitis
                  etc.)

               -  Prior pneumonitis/ILD secondary to EGFR inhibitors

          -  Mean QTc with Bazetts correction &gt; 470msec in screening ECG or history of familial
             long QT syndrome.

          -  Drugs that are highly dependent on CYP2D6 for metabolism are prohibited, since PF-804
             is a potent CYP2D6 inhibitor in in vitro assays. These inhibitors or inducers are
             prohibited from 7 days prior to the first dose until the end of treatment with PF-804.
             These include: S-metoprolol, propafenone, timolol, amitriptyline, clomipramine,
             desipramine, imipramine, paroxetine, haloperidol, risperidone, thioridazine, codeine,
             flecainide, mexilletine, tamoxifen, venlafaxine. Lidocaine may be used with clinical
             monitoring (including telemetry). Opiates such as morphine, oxycodone, dihydrocodeine,
             hydrocodone, and tramadol can be used as substitutes to replace codeine. Use of these
             opiates should be monitored for altered analgesia during treatment with PF-804 as they
             may be partly metabolized by CYP2D6. If PF-804 is administered with drugs which are
             P-glycoprotein (P-gp) substrates and have a narrow therapeutic index, monitoring for
             exaggerated effect and/or toxicities is recommended.

          -  Pregnancy or inadequate contraception. Women must be post-menopausal, surgically
             sterile, or use two reliable forms of contraception. Women of child-bearing potential
             must have a pregnancy test taken and proven negative within 7 days prior to
             randomization. Men must be surgically sterile or use a barrier method of
             contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Ellis, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Margaret and Charles Juravinski Cancer Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Penny Bradbury, MD</last_name>
    <role>Study Chair</role>
    <affiliation>NCIC Clinical Trials Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Millward, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sir Charles Gairdner Hospital - Nedlands</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shapiro, Stafford and Yee</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clintell, Inc.</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60077</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CER - Instituto Medico</name>
      <address>
        <city>Buenos Aires</city>
        <state>B1878DVB Bs. As.</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>COIBA Centro de Oncologia e Investigacion</name>
      <address>
        <city>Berazategui</city>
        <state>Provincia de Buenos Aires</state>
        <zip>01884</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Damic-Fundacion Rusculleda</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico San Roque</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <zip>T4000IAK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Concord Repatriation General Hospital</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. George Hospital, Cancer Care Centre</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>St. Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Calvary Mater Newcastle Hospital</name>
      <address>
        <city>Waratah</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Prince Charles Hospital</name>
      <address>
        <city>Chermside</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nambour General Hospital</name>
      <address>
        <city>Nambour</city>
        <state>Queensland</state>
        <zip>4560</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Hospital</name>
      <address>
        <city>Footscray</city>
        <state>Victoria</state>
        <zip>3011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frankston Hospital - Peninsula Oncology Centre</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geelong Hospital</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Hospital</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Oncologia e Radioterapia (COR) Mae de Deus</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>90840-440</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ESHO - Empresa de Servicos Hospitalares Ltda.</name>
      <address>
        <city>Brasilia</city>
        <state>Sao Paulo</state>
        <zip>01321-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacao Pio XII - Hospital de Cancer de Barretos</name>
      <address>
        <city>Barretos</city>
        <state>SP</state>
        <zip>14784-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisa Clinica do Hospital</name>
      <address>
        <city>Jahu</city>
        <state>SP</state>
        <zip>17210-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxion Hospital Dia Oncologia LTDA - Oxion</name>
      <address>
        <city>Belo Horizonte</city>
        <zip>30150-270</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Centro-Ljui-RS</city>
        <zip>98700-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nucleo de Oncologia da Bahia</name>
      <address>
        <city>Salvador</city>
        <zip>40170-110</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GRAM - Grupo de Assistencia Medica</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01224-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Abbotsford Centre</name>
      <address>
        <city>Abbotsford</city>
        <state>British Columbia</state>
        <zip>V2S 0C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Fraser Valley Cancer Centre</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Health Sciences Corporation</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <zip>E2L 4L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. H. Bliss Murphy Cancer Centre</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QEII Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre at Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centre of Southeastern Ontario at Kingston</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 5P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeridge Health Oshawa</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1G 2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Health Research Institute - General Division</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Algoma District Cancer Program</name>
      <address>
        <city>Sault Ste. Marie</city>
        <state>Ontario</state>
        <zip>P6B 0A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niagara Health System</name>
      <address>
        <city>St. Catharines</city>
        <state>Ontario</state>
        <zip>L2S 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Sciences North</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 5J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Windsor Regional Cancer Centre</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 2X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM - Hopital Notre-Dame</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University - Dept. Oncology</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allan Blair Cancer Centre</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saskatoon Cancer Centre</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro di Riferimento Oncologico - CRO</name>
      <address>
        <city>Aviano</city>
        <state>PN</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Busto Arsizio - P.O. Saronno</name>
      <address>
        <city>Saronno</city>
        <state>VA</state>
        <zip>21047</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. di Oncologia Medica Azienda Ospedaliera G Rummo</name>
      <address>
        <city>Benevento</city>
        <zip>82100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Croce</name>
      <address>
        <city>Fano</city>
        <zip>61032</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. di Oncologia Ospedale Villa Scassi</name>
      <address>
        <city>Genova Sampierdarena</city>
        <zip>16149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intstituto Scientifico Romangnolo</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.C. Terapie Integrate in Oncologia,</name>
      <address>
        <city>Messina</city>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.C. Oncologia Medica,</name>
      <address>
        <city>Messina</city>
        <zip>98158</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.C. di Oncologia U.L.S.S. 13</name>
      <address>
        <city>Mirano</city>
        <zip>30035</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dott. Fortunato Ciardiello,Cattedra Oncologia Medica</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unita Sperimentazioni Cliniche Istituto per lo</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UOC Oncologia Medica II Instituto Oncologio Veneto</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Maddalena, Dipartimento Oncologico</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda USL di Piacenza, Ospedale Gugliemimo Salieto</name>
      <address>
        <city>Piacenza</city>
        <zip>29100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Camillo-Forlanin</name>
      <address>
        <city>Rome</city>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I, Universita Sapienza</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Casa Sollievo della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo (FG)</city>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale E. Morelli-Sondalo</name>
      <address>
        <city>Sondalo</city>
        <zip>23039</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>GyeongGi-Do</city>
        <zip>443-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnan National University Hwasun Hospital</name>
      <address>
        <city>Jeonnam</city>
        <zip>519-763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul Veterans Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>134-791</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea,</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Central De La Fuerza Aerea Del Peru</name>
      <address>
        <city>Lima</city>
        <zip>18</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional Luis N. Saenz</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Oncologia y Radioterapia de</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perpetual Succour Hospital</name>
      <address>
        <city>Cebu City</city>
        <zip>6000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Makati Medical Center</name>
      <address>
        <city>Makati City</city>
        <zip>1229</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phillippine General Hospital</name>
      <address>
        <city>Manila</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chi-Mei Foundation Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>736</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chulalongkorn University</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ramathibodi Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital, Oncology Unit</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maharaj Nakorn Chiangmai Hospital</name>
      <address>
        <city>Chiangmai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Ellis PM, Shepherd FA, Millward M, Perrone F, Seymour L, Liu G, Sun S, Cho BC, Morabito A, Leighl NB, Stockler MR, Lee CW, Wierzbicki R, Cohen V, Blais N, Sangha RS, Favaretto AG, Kang JH, Tsao MS, Wilson CF, Goldberg Z, Ding K, Goss GD, Bradbury PA; NCIC CTG; Australasian Lung Cancer Trials Group; NCI Naples Clinical Trials Unit. Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. Lancet Oncol. 2014 Nov;15(12):1379-88. doi: 10.1016/S1470-2045(14)70472-3. Epub 2014 Oct 15.</citation>
    <PMID>25439692</PMID>
  </results_reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2009</study_first_submitted>
  <study_first_submitted_qc>October 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2009</study_first_posted>
  <results_first_submitted>September 19, 2014</results_first_submitted>
  <results_first_submitted_qc>October 23, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 27, 2014</results_first_posted>
  <last_update_submitted>July 12, 2016</last_update_submitted>
  <last_update_submitted_qc>July 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PF-804</title>
          <description>Study treatment arm</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Control arm</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="480"/>
                <participants group_id="P2" count="240"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="468"/>
                <participants group_id="P2" count="238"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="363"/>
                <participants group_id="P2" count="208"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Intercurrent Illness</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PF-00299804</title>
          <description>Patients receive oral PF-00299804 once daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
PF-00299804: PF-804 45 mg PO, daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Patients receive oral placebo once daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
Placebo: Placebo 45 mg PO, daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="480"/>
            <count group_id="B2" value="240"/>
            <count group_id="B3" value="720"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.5" lower_limit="32" upper_limit="86"/>
                    <measurement group_id="B2" value="65.5" lower_limit="34" upper_limit="90"/>
                    <measurement group_id="B3" value="64" lower_limit="32" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="236"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="244"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="172"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="288"/>
                    <measurement group_id="B2" value="144"/>
                    <measurement group_id="B3" value="432"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Philippines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="207"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thailand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peru</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>Median and 95% confidence intervals</description>
        <time_frame>42 Months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00299804</title>
            <description>Patients receive oral PF-00299804 once daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
PF-00299804: PF-804 45 mg PO, daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients receive oral placebo once daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
Placebo: Placebo 45 mg PO, daily</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Median and 95% confidence intervals</description>
          <population>ITT</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="480"/>
                <count group_id="O2" value="240"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.83" lower_limit="6.08" upper_limit="7.49"/>
                    <measurement group_id="O2" value="6.31" lower_limit="5.32" upper_limit="7.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The trial was designed to detect a 25% deduction in risk of death with PF-804 with 90% power using a 1-sided 2.5% level significance test. The sample size was estimated as 720 patients.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.506</p_value>
            <p_value_desc>Stratified by stratification factors at randomization except study center, but included K-Ras mutation status.1-sied p-value.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>Stratified by stratification factors at randomization except study center, but included K-Ras mutation status.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival in KRAS-WT Patients</title>
        <description>Median and 95% confidence intervals of Overall survival in KRAS-WT patients</description>
        <time_frame>42 Months</time_frame>
        <population>Patients with K-Ras mutation wild type</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00299804</title>
            <description>Patients receive oral PF-00299804 once daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
PF-00299804: PF-804 45 mg PO, daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients receive oral placebo once daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
Placebo: Placebo 45 mg PO, daily</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival in KRAS-WT Patients</title>
          <description>Median and 95% confidence intervals of Overall survival in KRAS-WT patients</description>
          <population>Patients with K-Ras mutation wild type</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.00" lower_limit="6.01" upper_limit="8.21"/>
                    <measurement group_id="O2" value="5.19" lower_limit="4.53" upper_limit="7.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.043</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Log Rank</method>
            <method_desc>Stratified by stratification factors at randomization except study center.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival in EGFR-mutant Patients</title>
        <description>Overall survival by EGFR-mutantion subgroups</description>
        <time_frame>42 Months</time_frame>
        <population>Patients with EGFR mutation</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00299804</title>
            <description>Patients receive oral PF-00299804 once daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
PF-00299804: PF-804 45 mg PO, daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients receive oral placebo once daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
Placebo: Placebo 45 mg PO, daily</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival in EGFR-mutant Patients</title>
          <description>Overall survival by EGFR-mutantion subgroups</description>
          <population>Patients with EGFR mutation</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.23" lower_limit="6.08" upper_limit="8.61"/>
                    <measurement group_id="O2" value="7.52" lower_limit="4.99" upper_limit="9.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.46</p_value>
            <p_value_desc>1-sided pvalue</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.44</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <description>progression were evaluated using the revised international criteria (1.1) proposed by the RECIST (Response Evaluation Criteria in Solid Tumours) committee</description>
        <time_frame>42 Months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00299804</title>
            <description>Patients receive oral PF-00299804 once daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
PF-00299804: PF-804 45 mg PO, daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients receive oral placebo once daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
Placebo: Placebo 45 mg PO, daily</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>progression were evaluated using the revised international criteria (1.1) proposed by the RECIST (Response Evaluation Criteria in Solid Tumours) committee</description>
          <population>ITT</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="480"/>
                <count group_id="O2" value="240"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.66" lower_limit="1.91" upper_limit="3.32"/>
                    <measurement group_id="O2" value="1.58" lower_limit="0.99" upper_limit="1.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Log Rank</method>
            <method_desc>Stratified by stratification factors at randomization except study center, but included K-Ras mutation status.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>0.79</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate</title>
        <description>Response were evaluated in this study using the revised international criteria (1.1) proposed by the RECIST (Response Evaluation Criteria in Solid Tumours) committee. BEST RESPONSE from the start of study treatment until the end of treatment were reported.Objective response rate is the sum of CR + PR divided by the total number of patients in each group.</description>
        <time_frame>42 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00299804</title>
            <description>Patients receive oral PF-00299804 once daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
PF-00299804: PF-804 45 mg PO, daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients receive oral placebo once daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
Placebo: Placebo 45 mg PO, daily</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate</title>
          <description>Response were evaluated in this study using the revised international criteria (1.1) proposed by the RECIST (Response Evaluation Criteria in Solid Tumours) committee. BEST RESPONSE from the start of study treatment until the end of treatment were reported.Objective response rate is the sum of CR + PR divided by the total number of patients in each group.</description>
          <population>ITT</population>
          <units>percentage of participants</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="480"/>
                <count group_id="O2" value="240"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" lower_limit="4.8" upper_limit="9.4"/>
                    <measurement group_id="O2" value="1.3" lower_limit="0.0" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>6.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.84</ci_lower_limit>
            <ci_upper_limit>20.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Toxicity as Measured by NCI CTCAE Version 4.0</title>
        <description>Number of participants with Toxicities by treatment received according to NCI CTCAE version 4.0</description>
        <time_frame>42 Months</time_frame>
        <population>As treated population</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00299804</title>
            <description>Patients receive oral PF-00299804 once daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
PF-00299804: PF-804 45 mg PO, daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients receive oral placebo once daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
Placebo: Placebo 45 mg PO, daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Toxicity as Measured by NCI CTCAE Version 4.0</title>
          <description>Number of participants with Toxicities by treatment received according to NCI CTCAE version 4.0</description>
          <population>As treated population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="477"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="467"/>
                    <measurement group_id="O2" value="223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>42 Months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PF-00299804</title>
          <description>Patients receive oral PF-00299804 once daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
PF-00299804: PF-804 45 mg PO, daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Patients receive oral placebo once daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
Placebo: Placebo 45 mg PO, daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="191" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Pericardial tamponade</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Corneal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Anal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Colonic obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Esophageal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Obstruction gastric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Death NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Infusion site extravasation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Sudden death NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Lymph gland infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Mucosal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Other infections and infestations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Scrotal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Other neoplasms benign, malignant and unspecified</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Tumor pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Dysphasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Intracranial hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Ischemia cerebrovascular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Other nervous system disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Sinus pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Transient ischemic attacks</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Personality change</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Hoarseness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Other skin and subcutaneous tissue disorders</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Stevens-Johnson syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Other vascular disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="465" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="219" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="120" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="380" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" subjects_affected="206" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="168" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="134" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="254" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="115" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="142" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="222" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumor pain</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchopulmonary hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="233" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="108" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="276" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="132" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="171" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Other skin and subcutaneous tissue disorders</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" subjects_affected="283" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Despite the eligibility requirement for tumor samples, samples were not available or inadequate for translational studies in 30 - 40% of patients. This does limits the power of the secondary analyses examining biomarker driven outcomes.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Keyue Ding</name_or_title>
      <organization>NCIC Clinical Trails Group</organization>
      <phone>1-613-533-6000 ext 77705</phone>
      <email>kding@ctg.queensu.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

